Last reviewed · How we verify
NCT05817604: SABINA
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
trial testing SBRT in Kidney Neoplasm in 60 participants. Participants enrolled and being followed up; not accepting new ones.
1 May 2026
Quick facts
| Lead sponsor | Consorci Sanitari de Terrassa |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 March 2023 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2028 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- SBRT — full drug profile →
Conditions studied
- Kidney Neoplasm — all drugs for Kidney Neoplasm →
- Renal Cancer — all drugs for Renal Cancer →
- Inoperable Disease — all drugs for Inoperable Disease →
- SBRT — all drugs for SBRT →
Sponsor
Consorci Sanitari de Terrassa — full company profile →
Who can join
Adults 18 to 100, any sex, with Kidney Neoplasm or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05817604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SBRT
Trials testing the same drug.
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
- NCT07410234 — Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity · Phase 2 · not yet recruiting
Other recruiting trials for Kidney Neoplasm
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07234409 — Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Mana · NA · recruiting
- NCT06903312 — Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. · Phase 4 · recruiting
- NCT06467097 — Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma · Phase 3 · recruiting
- NCT05887245 — Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy · active not recruiting
Other Consorci Sanitari de Terrassa trials
Trials by the same sponsor.
- NCT07467408 — Treatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) · not yet recruiting
- NCT07210892 — Paramedian Incidence Angles in Spinal Anaesthesia · recruiting
- NCT06956794 — Multimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Wom · NA · active not recruiting
- NCT06713460 — Emotional Intelligence Intervention to Improve Mental Well-Being of Adolescents With Emotional Distress (BEAM) · NA · recruiting
- NCT07040748 — Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05817604 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari de Terrassa
- Last refreshed: 10 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05817604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing